Last updated 11 January 2021 +show all updates
-
Updated ‘National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests’ to clarify the procurement process and to reflect the number of technologies currently in the TVG pipeline.
-
Updated the ‘National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests’ document to add a new validated technology, Abbott.
-
Updated the ‘National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests’ document to delete a validated technology (Latus) and add a new validated technology (Nonacus).
-
Updated the ‘National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests’ document to update the ‘Products in the pipeline’ table and add a new validated technology, Latus.
-
Updated ‘National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests’: added guidance for antibody test manufacturers about registering interest; added that an alternative technical validation route will be required for any non-machine based LFT and home testing kits; and removed Tenders Electronic Daily as a source of further procurement opportunities.
-
Added Oxford Nanopore: LamPORE: RNA RT-qPCR to validated technology table in ‘National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests’.
-
Updated ‘National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests’ to reflect the number of technologies currently in the TVG pipeline.
-
Updated ‘National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests’ to add a new validated technology (QuantuMDx), edited links under ‘Publication of results’ and amended title of ‘First wave of non-machine based lateral flow technology (LFT) assessment’ to ‘First wave of lateral flow test and non-machine based LFT assessment’.
-
In the attachment National technical validation process for manufacturers of SARS-CoV-2 (COVID-19), updated information about technologies in the pipeline, added new information about validations concluded or paused and added new information and reports on validated technology.
-
In ‘National technical validation process for manufacturers of SARS-CoV-2 (COVID-19) tests’, updated information about technologies in the pipeline.
-
Small amendments made to first 2 paragraphs in ‘National technical validation process for manu
Source link